Taro Company Profile
✉ Email this page to a colleague
What is the competitive landscape for TARO
TARO has one hundred and twenty-eight approved drugs.
There are two US patents protecting TARO drugs. There is one tentative approval on TARO drugs.
Summary for Taro
| US Patents: | 2 |
| Tradenames: | 90 |
| Ingredients: | 79 |
| NDAs: | 128 |
| Patent Litigation for Taro: | See patent lawsuits for Taro |
| PTAB Cases with Taro as petitioner: | See PTAB cases with Taro as petitioner |
Drugs and US Patents for Taro
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Taro | FLUPHENAZINE HYDROCHLORIDE | fluphenazine hydrochloride | TABLET;ORAL | 215674-002 | Apr 14, 2022 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| Taro | PERAMPANEL | perampanel | TABLET;ORAL | 209538-001 | Nov 25, 2025 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| Taro Pharms North | PSORCON | diflorasone diacetate | CREAM;TOPICAL | 020205-001 | Nov 20, 1992 | DISCN | Yes | No | ⤷ Start Trial | ⤷ Start Trial | |||||
| Taro | CHILDREN'S FEXOFENADINE HYDROCHLORIDE ALLERGY | fexofenadine hydrochloride | SUSPENSION;ORAL | 208123-001 | Nov 9, 2017 | OTC | No | No | ⤷ Start Trial | ⤷ Start Trial | |||||
| Taro | CETIRIZINE HYDROCHLORIDE HIVES RELIEF | cetirizine hydrochloride | TABLET;ORAL | 078072-002 | Jul 22, 2009 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | |||||
| Taro | NORTRIPTYLINE HYDROCHLORIDE | nortriptyline hydrochloride | CAPSULE;ORAL | 075520-002 | May 8, 2000 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| Taro | AMIODARONE HYDROCHLORIDE | amiodarone hydrochloride | TABLET;ORAL | 076362-002 | Dec 2, 2003 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | |||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Taro
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Taro | OVIDE | malathion | LOTION;TOPICAL | 018613-001 | Aug 2, 1982 | 7,977,324 | ⤷ Start Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for TARO drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Topical Spray | 0.25% | ➤ Subscribe | 2013-12-18 |
| ➤ Subscribe | Topical Lotion | 0.5% | ➤ Subscribe | 2011-03-16 |
International Patents for Taro Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Japan | 5474347 | ⤷ Start Trial |
| Canada | 2612578 | ⤷ Start Trial |
| Japan | 2009500422 | ⤷ Start Trial |
| China | 101287374 | ⤷ Start Trial |
| European Patent Office | 1898707 | ⤷ Start Trial |
| Brazil | PI0612686 | ⤷ Start Trial |
| Japan | 2013032405 | ⤷ Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Taro Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1856135 | CA 2020 00018 | Denmark | ⤷ Start Trial | PRODUCT NAME: FOSTAMATINIB OR A PHARMACEUTICALLY ACCEPTABLE SALT OF FOSTAMATINIB, OR A HYDRATE, SOLVATE OR N-OXIDE OF FOSTAMATINIB OR THE PHARMACEUTICALLY ACCEPTABLE SALT OF FOSTAMATINIB, ESPECIALLY FOSTAMATINIB DISODIUM, OPTIONALLY IN FORM OF A HYDRATE; REG. NO/DATE: EU/1/19/1405 20200113 |
| 1856135 | SPC/GB20/016 | United Kingdom | ⤷ Start Trial | PRODUCT NAME: FOSTAMATINIB OR A PHARMACEUTICALLY ACCEPTABLE SALT OF FOSTAMATINIB, OR A HYDRATE, SOLVATE OR N-OXIDE OF FOSTAMATINIB OR THE PHARMACEUTICALLY ACCEPTABLE SALT OF FOSTAMATINIB, ESPECIALLY FOSTAMATINIB DISODIUM, OPTIONALLY IN FORM OF A HYDRATE; REGISTERED: UK EU/1/19/1405 (NI) 20200113; UK PLGB 12930/0022 20200113; UK PLGB 12930/0023 20200113 |
| 2203431 | 1590018-6 | Sweden | ⤷ Start Trial | PRODUCT NAME: DASABUVIR OR A SALT THEREOF, INCLUDING DASABUVIR SODIUM MONOHYDRATE; REG. NO/DATE: EU/1/14/983 20150119 |
| 1499331 | SPC/GB13/034 | United Kingdom | ⤷ Start Trial | PRODUCT NAME: IZINOVA CONCENTRATE FOR ORAL SOLUTION. THE ACTIVE SUBSTANCE IS A MIXTURE OF 3 SALTS:SODIUM SULPHATE ANHYDROUS, MAGNESIUM SULPHATE HEPTAHYDRATE AND POTASSIUM SULPHATE.; REGISTERED: BE BE434323 20130220; UK PL34926/0016 20130313 |
| 1261606 | SPC/GB09/008 | United Kingdom | ⤷ Start Trial | SUPPLEMENTARY PROTECTION CERTIFICATE NO SPC/GB09/008 GRANTED TO BAYER INTELLECTUAL PROPERTY GMBH IN RESPECT OF THE PRODUCT RIVAROXABAN AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS, HYDRATES, HYDRATES OF THE SALTS AND PRODRUGS, THE GRANT OF WHICH WAS ADVERTISED IN JOURNAL NO 6352 DATED 16 FEBRUARY 2011 HAS HAD ITS MAXIMUM PERIOD OF DURATION CORRECTED, SUBJECT TO THE PAYMENT OF THE PRESCRIBED FEES IT WILL EXPIRE ON 01 OCTOBER 2023. |
| 0957929 | SPC/GB06/021 | United Kingdom | ⤷ Start Trial | PRODUCT NAME: PEGAPTANIB, PREFERABLY IN THE FORM OF ITS SODIUM SALT; REGISTERED: UK EU/1/05/325/001 20060201 |
| 1912999 | 1490062-5 | Sweden | ⤷ Start Trial | PRODUCT NAME: SIMEPREVIR, OR A SALT THEREOF, INCLUDING SIMEPREVIR SODIUM; REG. NO/DATE: EU/1/14/924 20140516 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
